Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ICLR - IE0005711209 - Common Stock

182.835 USD
-0.84 (-0.46%)
Last: 12/26/2025, 8:00:02 PM
182.835 USD
0 (0%)
After Hours: 12/26/2025, 8:00:02 PM
Fundamental Rating

5

Overall ICLR gets a fundamental rating of 5 out of 10. We evaluated ICLR against 57 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

ICLR had positive earnings in the past year.
In the past year ICLR had a positive cash flow from operations.
In the past 5 years ICLR has always been profitable.
Each year in the past 5 years ICLR had a positive operating cash flow.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

ICLR's Return On Assets of 3.63% is fine compared to the rest of the industry. ICLR outperforms 75.44% of its industry peers.
ICLR has a better Return On Equity (6.42%) than 75.44% of its industry peers.
With a decent Return On Invested Capital value of 6.74%, ICLR is doing good in the industry, outperforming 75.44% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 13.99%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.74%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.63%
ROE 6.42%
ROIC 6.74%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

With a decent Profit Margin value of 7.40%, ICLR is doing good in the industry, outperforming 75.44% of the companies in the same industry.
ICLR's Profit Margin has declined in the last couple of years.
ICLR has a better Operating Margin (13.99%) than 75.44% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
ICLR has a Gross Margin of 28.15%. This is in the lower half of the industry: ICLR underperforms 77.19% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 13.99%
PM (TTM) 7.4%
GM 28.15%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
ICLR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.10 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ICLR (2.10) is comparable to the rest of the industry.
The Debt to FCF ratio of ICLR is 3.53, which is a good value as it means it would take ICLR, 3.53 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ICLR (3.53) is better than 78.95% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
ICLR has a Debt to Equity ratio of 0.31. This is comparable to the rest of the industry: ICLR outperforms 49.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 3.53
Altman-Z 2.1
ROIC/WACC0.76
WACC8.85%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

ICLR has a Current Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR's Current ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 85.96% of its industry peers.
A Quick Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
The Quick ratio of ICLR (1.06) is worse than 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

4

3. Growth

3.1 Past

ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has decreased by -2.46% in the past year.
The Revenue has been growing by 24.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%

3.2 Future

The Earnings Per Share is expected to grow by 5.61% on average over the next years.
The Revenue is expected to grow by 2.38% on average over the next years.
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20 25

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 13.86, the valuation of ICLR can be described as correct.
96.49% of the companies in the same industry are more expensive than ICLR, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.92. ICLR is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 13.40 indicates a correct valuation of ICLR.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 96.49% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. ICLR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 13.86
Fwd PE 13.4
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 94.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.48
EV/EBITDA 11.1
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.91
EPS Next 2Y-1.27%
EPS Next 3Y2.47%

0

5. Dividend

5.1 Amount

ICLR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ICON PLC

NASDAQ:ICLR (12/26/2025, 8:00:02 PM)

After market: 182.835 0 (0%)

182.835

-0.84 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-22 2025-10-22/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners102.95%
Inst Owner Change1.3%
Ins Owners0.66%
Ins Owner ChangeN/A
Market Cap13.96B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.67 (14.68%)
Short Float %3.68%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-0.06%
PT rev (3m)-4.74%
EPS NQ rev (1m)-0.09%
EPS NQ rev (3m)-4.74%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-1.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)1.09%
Valuation
Industry RankSector Rank
PE 13.86
Fwd PE 13.4
P/S 1.72
P/FCF 14.48
P/OCF 12.24
P/B 1.5
P/tB N/A
EV/EBITDA 11.1
EPS(TTM)13.19
EY7.21%
EPS(NY)13.65
Fwd EY7.46%
FCF(TTM)12.63
FCFY6.91%
OCF(TTM)14.93
OCFY8.17%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.91
Graham Number190.47
Profitability
Industry RankSector Rank
ROA 3.63%
ROE 6.42%
ROCE 8.53%
ROIC 6.74%
ROICexc 6.98%
ROICexgc 176.34%
OM 13.99%
PM (TTM) 7.4%
GM 28.15%
FCFM 11.9%
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 3.53
Debt/EBITDA 1.89
Cap/Depr 45.31%
Cap/Sales 2.17%
Interest Coverage 250
Cash Conversion 74.92%
Profit Quality 160.84%
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z 2.1
F-Score6
WACC8.85%
ROIC/WACC0.76
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.69%
EPS Next 2Y-1.27%
EPS Next 3Y2.47%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.44%
Revenue Next 2Y-0.9%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.2%
EBIT Next 3Y1.96%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%

ICON PLC / ICLR FAQ

Can you provide the ChartMill fundamental rating for ICON PLC?

ChartMill assigns a fundamental rating of 5 / 10 to ICLR.


What is the valuation status of ICON PLC (ICLR) stock?

ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.


Can you provide the profitability details for ICON PLC?

ICON PLC (ICLR) has a profitability rating of 6 / 10.


How financially healthy is ICON PLC?

The financial health rating of ICON PLC (ICLR) is 5 / 10.


What is the earnings growth outlook for ICON PLC?

The Earnings per Share (EPS) of ICON PLC (ICLR) is expected to decline by -4.69% in the next year.